Health Canada's updated guidance on biosimilar biologic drugs marks a significant shift in the regulatory framework governing biologics in Canada, with important implications for innovators, biosimilar manufacturers, and the broader life sciences sector.

Speaking recently with Lexpert, Adam Heckman, a partner in Gowling WLG's Intellectual Property Group, discussed the significance of Health Canada's revised approach and what it means for intellectual property strategies and biosimilar development in Canada.

To read the full article, click the link below (subscription may be required):

About Gowling WLG's Intellectual Property Group

Gowling WLG is a full-service firm comprising 1,500 professionals with strength across all areas of business law and litigation. With leading IP practices in Canada, China, the UAE, the UK and Europe, and—via our exclusive association with JurisAsia LLC—Singapore, and a network of trusted agents worldwide, we help IP owners overcome complex obstacles and optimize new opportunities—wherever business takes them. Learn more